Institutional members access full text with Ovid®

Share this article on:

Effect of Rebamipide Ophthalmic Suspension on Optical Quality in the Short Break-up Time Type of Dry Eye

Koh, Shizuka MD; Inoue, Yasushi MD; Sugmimoto, Toshiki MD; Maeda, Naoyuki MD; Nishida, Kohji MD

doi: 10.1097/ICO.0b013e318294f97e
Clinical Science

Purpose: To determine the effect of rebamipide ophthalmic suspension on optical quality in patients with dry eye with short break-up time (BUT) of the tear film.

Methods: Twenty-six eyes of 16 patients with the short BUT type of dry eye were enrolled and treated with 2% rebamipide ophthalmic suspension. At baseline and at 2 and 4 weeks after initiating the treatment, the serial corneal higher-order aberrations (HOAs), BUT, fluorescein staining, and Schirmer test were measured. Patients were asked to complete questionnaires about the changes in dry eye–related ocular symptoms after the treatment.

Results: Before the treatment, the pattern of postblink corneal HOAs for 10 seconds showed a sawtooth pattern, with a marked upward curve that increased after blinking. Treatment with rebamipide for 4 weeks significantly (P < 0.05) improved the postblink corneal HOAs and stabilized the pattern of the corneal HOAs. Significant increases in the tear film BUT were seen 2 and 4 weeks after the treatment (P < 0.001 for both comparisons).

Conclusions: Rebamipide administered to treat the short BUT type of dry eye significantly improved optical quality because of the improvement in tear stability.

*Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan;

Inoue Eye Clinic, Okayama, Japan; and

Okayamaminami Eye Clinic, Okayama, Japan.

Reprints: Shizuka Koh, Department of Ophthalmology, Osaka University Graduate School of Medicine, Room E7, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan (e-mail:

Supported in part by a Grant-in-Aid No. 22791659 (to Dr Koh) for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

The authors state that they have no proprietary interest in the products named in this article.

Received February 12, 2013

Accepted March 31, 2013

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.